Treatment exposure and efficacy
Among 29 patients, 34.5% (10/29) patients had a maximum tolerated dose of 3 mg fruquintinib, 51.7% (15/29) patients had a maximum tolerated dose of 4 mg, and only 13.8% (4/29) patients could tolerate a therapeutic dose of 5 mg. The weekly dosing history for patients up to Week 1 of Cycle 3 is summarized in Figure Swimmer plot presenting dosing history up to Week 1 of Cycle 3.Maximum tolerable dose and efficacy with fruquintinib treatment.Survival outcomes with fruquintinib treatment. (A) The overall survival curve of the entire cohort. (B) The progression‐free survival curve of the entire cohort.Univariate analysis of progression‐free survival correlations in 29 patients using a Cox proportion hazard model.Univariate analysis of overall survival correlations in 29 patients using a Cox proportion hazard model.